Browsing: Ultomiris

Ultomiris has become one of the most important treatments in the rare disease space because of its ability to reduce the burden of chronic infusion therapy while improving patient outcomes across paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). As a long-acting C5 complement inhibitor, Ultomiris was developed as…